Integra LifeSciences (IART) executives told attendees at the Wells Fargo 21st Annual Healthcare Conference on Sept. 9 that the company's recovery from product recalls is accelerating, with management reaffirming full-year 2026 organic growth guidance of 0.8% to 3.3% and projecting a revenue step-up of roughly $25 million in the fourth quarter.
Chief Financial Officer Lea Knight and Chief Commercial Officer Michael McBreen, speaking with Wells Fargo med-tech analyst Ross Osborn, outlined progress across the company's surgical-device portfolio as supply chain operations return to normal. Revenue over the last twelve months totaled $1.65 billion, reflecting 1.6% growth, with a gross profit margin of approximately 57%. Q2 2026 EBITDA margin came in at 18.7%, and the company expects full-year margin expansion of about 100 basis points compared with 2025—driven by roughly 60 basis points from gross margin improvement and 40 basis points from operating expense efficiencies.
Free cash flow is on track to reach about $150 million in 2026, bolstered by a first-half operating cash-flow improvement of approximately $35 million. Cost-cutting actions implemented in Q1 are expected to deliver $25 million to $30 million in savings over three quarters, with an incremental $10 million to $15 million anticipated in 2027. Cash-flow benefits also include avoidance of an $11 million earnout payment made in the first half and a $30 million reduction from winding down EU MDR compliance spending and Braintree startup costs.
Analysts forecast EPS of $2.46 in 2026, marking a return to profitability. The stock was quoted around $16.14, well below an InvestingPro fair-value estimate of $21.14, though it has gained 70% over the past six months and 31% year-to-date.
On the operational side, the Braintree manufacturing facility is now fully operational, described by management as a major milestone enabling product relaunches and supply restoration. PriMatrix and Durepair were relaunched in Q4 2025 and have recovered more than half of pre-recall revenue within twelve months. SurgiMend is scheduled to relaunch from Braintree in Q4 2026 as a 510(k) product, with a PMA application for an expanded breast-reconstruction indication expected in 2027. A new neurosurgery product, Liberties, is planned for 2027 and combines Bactiseal infection-prevention features with anti-clogging technology for external ventricular drainage.
In the ENT segment, Q2 revenue declined about 2% due to reimbursement pressure on sinus balloons, while specialty surgery posted low single-digit growth. Reimbursement for tissue reconstruction products currently stands at $127 per square centimeter. Capital equipment—representing about 6% of revenue—includes devices priced up to $225,000 for CUSA, which received two new FDA indications over the past year for gynecological and cardiac procedures.
Knight noted that pre-2023 benchmarks showed the business performing closer to market growth rates, with gross margins in the mid-60s, EBITDA margins in the mid-20s, and free cash flow topping $200 million annually. "That is what is possible for this business," she said. McBreen added that with products returning to market, the sales effort is shifting toward clinically focused conversations to drive growth. "Our customers have not lost faith and trust in our products," he said.
